Sponsored TestingPrograms

PreventionGenetics is proud to partner with biopharmaceutical companies to offer no-cost sponsored testing programs to patients who qualify. Through these partnerships we are paving the way for more timely and effective intervention--improving lives through genetic testing.

No-Cost Genetic Testing Program for Rare Calcification Disorders

This program sponsored by Inozyme Pharma offers global, no-cost genetic testing for the Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP binding cassette subfamily C member 6 (ABCC6) genes. These genes are implicated in two rare, severe, debilitating calcification disorders: ENPP1 Deficiency and ABCC6 Deficiency. Both these disorders can manifest as generalized arterial calcification of infancy (GACI) type 1 in infancy and then autosomal recessive hypophosphatemic rickets type 2 (ARHR2) in the case of ENPP1 Deficiency or Pseudoxanthoma elasticum (PXE) in the case of ABCC6 Deficiency post infancy.

In partnership with Modis Therapeutics, this No-Cost Genetic Testing Program is available to individuals with a suspected or clinical diagnosis of Thymidine Kinase 2 Deficiency (TK2d), a mitochondrial DNA depletion disorder. TK2d is a rare, underdiagnosed, and often fatal genetic disorder, which can present at any age, from infancy to adulthood.

No-cost Sponsored Testing Program for Rare Genetic Disorders of Obesity

Uncovering Rare Obesity is a program sponsored by Rhythm Pharmaceuticals. The sponsored genetic testing program includes a 40 gene panel of different genes potentially associated with several rare genetic disorders of obesity. Tests can only be ordered by licensed US healthcare providers for their US-resident patients. The goal of Uncovering Rare Obesity is to expand access to genetic testing for individuals who may have a rare genetic disorder of obesity.

We use cookies and other tracking technologies to improve your browsing experience on our website, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies.